Beijing Hotgen Biotech Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Changqing Lin

Chief executive officer

CN¥6.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	24.3%
Management average tenure	no data
Board average tenure	1.8yrs

Recent management updates

Recent updates

There's Reason For Concern Over Beijing Hotgen Biotech Co., Ltd.'s (SHSE:688068) Massive 28% Price Jump

Mar 06

CEO

Changqing Lin (47 yo)

no data

Tenure

CN¥6,129,000

Compensation

Mr. Changqing Lin serves as Chairman of the Board and General Manager at Beijing Hotgen Biotech Co., Ltd.

Board Members

Name	Position	Tenure	Compensation	Ownership
Changqing Lin	Chairman & GM	no data	CN¥6.13m	24.25% CN¥ 647.2m
Shen Qi	Director	no data	no data	no data
Jing Li	Chairman of the Supervisory Board	no data	no data	no data
Qi Gao	Supervisor	2.8yrs	no data	no data
Xiaoli Liu	Director	1.8yrs	CN¥1.94m	0.015% CN¥ 397.7k
Changyuan Yu	Independent Director	1.8yrs	CN¥60.00k	no data

1.8yrs

Average Tenure

46yo

Average Age

Experienced Board: 688068's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Beijing Hotgen Biotech Management

Management criteria checks 1/4

Key information

Recent management updates

Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Recent updates

Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: EPS: CN¥0.31 (vs CN¥10.33 in FY 2022)

Beijing Hotgen Biotech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

There's Reason For Concern Over Beijing Hotgen Biotech Co., Ltd.'s (SHSE:688068) Massive 28% Price Jump

Full year 2023 earnings released: EPS: CN¥0.34 (vs CN¥10.33 in FY 2022)

Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 150 million worth of its shares.

Beijing Hotgen Biotech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥3.12 profit in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥2.27 in 2Q 2022)

Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: EPS: CN¥12.13 (vs CN¥23.74 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥3.12 (vs CN¥0.26 in 3Q 2021)

Investor sentiment improved over the past week

Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 300 million worth of its shares.

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥13.69 (vs CN¥0.018 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.67 (vs CN¥0.01 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥1.79 (vs CN¥0.67 in FY 2019)

New 90-day low: CN¥34.59

New 90-day low: CN¥37.10

New 90-day low: CN¥41.40

Beijing Hotgen Biotech Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥46.23

New 90-day low - CN¥50.51

Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age